Helicase primase inhibitors (HPIs) are efficacious for therapy of human herpes simplex virus (HSV) disease in an infection mouse model

In conclusion the preclinical studies of the novel HPI compounds showed superior efficacy in comparison to the current standard HSV treatment represented by VACV with respect to the survival according humane endpoints, the clinical score and virus load in lungs and brains. Thus, candidates of this new drug class are promising antivirals of HSV infections and further translation into clinical trials is warranted.PMID:34666109 | DOI:10.1016/j.antiviral.2021.105190

Source: Antiviral Research - October 19, 2021 Category: Virology Authors: Nadja Uhlig Anne-Kathrin Donner Christian Gege Franziska Lange Gerald Kleymann Thomas Grunwald Source Type: research